Forbion Capital Partners

Citryll is a private pharmaceutical company based in Oss, The Netherlands, founded in 2015. The company focuses on developing drugs aimed at treating autoimmune diseases and other human health conditions. Citryll's innovative approach involves the manipulation of the formation, function, and clearance of neutrophil extracellular traps (NETs) that are influenced by the protein citrullination pathway, specifically through the action of Peptidylarginine Deiminase (PAD) enzymes. This research supports medical professionals in addressing various serious conditions, including lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis, and organ damage resulting from sepsis.

enGene is a developer of a mucosal immunotherapy platform designed to treat inflammatory bowel disease and diabetes. The company's mucosal immunotherapy platform has developed a flexible nucleotide delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expression levels, enabling physicians and doctors to regenerate physiologic, meal-regulated insulin secretion from the gut of subjects with diabetes.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company focused on developing a novel class of medicines known as Bicycles, which are synthetic short peptides designed to stabilize their structural geometry through two loops. The company primarily targets oncology indications with significant unmet medical needs. Its lead product candidate, BT1718, is a Bicycle Toxin Conjugate currently undergoing Phase I/IIa clinical trials aimed at tumors expressing Membrane Type 1 matrix metalloprotease. Other oncology candidates include BT5528, also in Phase I/IIa trials targeting EphA2, and BT8009, which is in preclinical studies for Nectin-4. Additionally, Bicycle Therapeutics is developing THR-149, a plasma kallikrein inhibitor that has completed Phase I trials for diabetic macular edema. The company collaborates with various biopharmaceutical organizations to advance programs in areas like anti-infectives and cardiovascular health. Founded in 2009, Bicycle Therapeutics is headquartered in Cambridge, United Kingdom.

Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers. Its lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. The company was founded in 2022 and is based in London, England.

Progentos Therapeutics is focused on developing innovative treatments for multiple sclerosis by harnessing the body's natural repair mechanisms. The company creates novel small-molecule therapeutics aimed at activating oligodendrocyte progenitor cells, which are crucial for myelin regeneration. This approach seeks to help patients recover lost functions and enhance their overall quality of life. Through its targeted research and development efforts, Progentos Therapeutics is dedicated to addressing the challenges associated with chronic diseases, particularly in the context of neurological disorders.

Seamless Therapeutics is focused on advancing gene editing through an innovative technology platform that reprograms recombinases, a versatile class of enzymes. The company's approach aims to restore health in patients with severe medical conditions safely and precisely. By developing disease-modifying product candidates, Seamless Therapeutics seeks to broaden the therapeutic applications of gene editing, ultimately enhancing treatment options for patients.

Engrail is forging a new direction to reduce the enormous burden of diseases that impact the nervous system. We unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverage our flexible transaction model to advance assets with validated mechanisms and efficiently move them through development to commercialization.

Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery.

Calluna Pharma is a clinical-stage company focused on developing innovative therapies that leverage the body's immune system to treat various immunological diseases. The company has established a strong pipeline of selective antibodies aimed at addressing unmet clinical needs across a range of conditions. Its approach includes precision targeting of upstream innate immune amplifiers and the disruption of disease-associated downstream signaling pathways, all while ensuring a favorable safety profile for its therapeutic candidates. Through its research and development efforts, Calluna Pharma aims to transform treatment options for patients suffering from immunological disorders.

Kynexis is focused on developing a precision medicine aimed at treating cognitive impairment associated with schizophrenia (CIAS). The company's innovative research utilizes a human biology-based approach to identify causal biomarkers that inform its mechanism of action during clinical development. Additionally, Kynexis employs a human genetics strategy to pinpoint specific sub-populations of patients who are likely to respond positively to the treatment. Through these methods, Kynexis seeks to enhance brain function in individuals affected by schizophrenia, addressing a critical need in mental health care.

Rampart Bioscience specializes in the development of gene medicines aimed at providing long-lasting treatments for a broad array of diseases. The company has created proprietary development and delivery platforms that enable the production of optimized therapeutics in a non-viral format. By integrating expertise from various scientific disciplines, such as gene delivery, protein sciences, and clinical translation, Rampart Bioscience focuses on assisting patients with genetically driven conditions, ultimately enhancing the effectiveness and safety of therapeutic interventions.

Long Description: Aiolos Bio is a biotech company focused on developing therapies for respiratory diseases like asthma as well as other immune conditions. The company is initially focused on advancing AIO-001, a monoclonal antibody therapy for moderate-to-severe asthma that only requires dosing every 6 months. Aiolos Bio was founded by an accomplished team with decades of drug development experience and leadership in the biotech industry.

Mariana Oncology is a biotechnology company focused on developing radiopharmaceuticals designed to target cancer cells using radioactive drugs. The company leverages expertise in ligand discovery, radiochemistry, and radiobiology, along with oncology translational and clinical research, to create a diverse pipeline aimed at treating various solid tumor types. By advancing the use of radiomedicines, Mariana Oncology seeks to enhance treatment options for medical professionals in their fight against cancer.

AAVantgarde Bio is a biotechnology company focused on developing gene therapies specifically for inherited retinal disorders. The company utilizes proprietary Adeno-Associated Viral (AAV) vector platforms to overcome the limitations associated with the cargo capacity of traditional AAV vectors. This innovative approach allows for the delivery of large genes to both ocular and non-ocular tissues, enhancing the potential for effective gene therapy solutions. By addressing these challenges, AAVantgarde Bio aims to improve treatment outcomes for patients suffering from these genetic conditions.

Seamless Therapeutics is focused on advancing gene editing through an innovative technology platform that reprograms recombinases, a versatile class of enzymes. The company's approach aims to restore health in patients with severe medical conditions safely and precisely. By developing disease-modifying product candidates, Seamless Therapeutics seeks to broaden the therapeutic applications of gene editing, ultimately enhancing treatment options for patients.

Noema Pharma AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing therapeutic products and therapies for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts aim to address disabling symptoms in conditions affecting the nervous system, including Tuberous Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By creating novel therapies, Noema Pharma seeks to improve the quality of life and patient outcomes for individuals suffering from these rare conditions.

NewAmsterdam Pharma is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cardio-metabolic diseases. The company aims to enhance patient care for individuals with metabolic disorders by addressing the shortcomings of currently available treatments. Its leading product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor designed to effectively lower LDL cholesterol levels while potentially overcoming the limitations associated with existing therapies.

CatalYm GmbH, founded in 2016 and based in Munich, Germany, is a biotechnology company focused on developing innovative immunotherapies for cancer patients. The company has identified GDF-15 as a key regulator of the immune system within the tumor microenvironment. By neutralizing GDF-15, CatalYm aims to enhance the immune response against solid tumors, potentially leading to meaningful clinical outcomes. Its CTL-002 program is designed to demonstrate clinical proof-of-concept across multiple solid tumor indications, offering the prospect of expanding treatment options for cancer patients. Through its approach, CatalYm seeks to transform the tumor microenvironment, making tumors more accessible to the immune system and improving both survival rates and quality of life for patients.

Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers. Its lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. The company was founded in 2022 and is based in London, England.

Anaveon are developing IL-2 complexes which selectively promote effector T cell functions. Our compounds act as effective immune adjuvants with a broad therapeutic window and marked preclinical efficacy against cancer either as monotherapy or in combination with other therapies.

Prilenia is a clinical-stage biotechnology company focused on developing innovative treatments for neurodegenerative and neurodevelopmental disorders. Founded in 2018, the company operates from locations in Israel, the Netherlands, and Boston. Its primary asset is Pridopidine, an oral drug candidate that has demonstrated an established safety profile and shows promise in treating various movement disorders and neurodegenerative diseases in both adults and children. Prilenia aims to enhance the functional capacity of patients, particularly those undergoing early hemodialysis, by addressing the underlying challenges posed by these conditions.

NeRRe Therapeutics Ltd. is a biotechnology company based in Stevenage, United Kingdom, specializing in the development of neurokinin (NK) receptor antagonists for clinical and preclinical use. Founded in 2012, the company focuses on creating innovative therapies to address conditions related to neuronal hypersensitivity. Its lead asset, orvepitant, is an oral NK-1 antagonist aimed at treating intense pruritus caused by targeted anti-cancer therapies. In addition to orvepitant, NeRRe's portfolio includes NT-814, a dual NK-1 and NK-3 antagonist, NT-949, a Phase I-ready NK-1 antagonist, and NT-432, a clinical candidate. The company's work targets common and chronic conditions, offering new treatment options for patients suffering from refractory or unexplained cough and other debilitating symptoms.

Numab is a biotechnology company focused on developing antibody-based therapeutics for severe diseases, including chronic inflammation and cancer. The company employs a plug-and-play platform that minimizes the randomness typically associated with the drug discovery process, allowing for the predictable creation of multispecific biotherapeutics. This platform facilitates the development of mono- or multispecific antibody fragment-based therapeutics with customized pharmacokinetic properties, enabling the healthcare sector to address multiple therapeutic targets simultaneously. Through its innovative approach, Numab aims to enhance the effectiveness of immunotherapies in treating complex medical conditions.

Gyroscope is a clinical-stage gene therapy company that specializes in developing treatments for retinal diseases, particularly focusing on Age-related Macular Degeneration (AMD), a major cause of blindness. The company leverages advancements in understanding the complement system's role in eye diseases and uses gene therapy as a therapeutic approach. Gyroscope's lead investigational therapy, GT005, is designed to be administered as a one-time treatment under the retina, aiming to restore balance to an overactive complement system by enhancing the production of the Complement Factor I protein. Currently, GT005 is undergoing evaluation in multiple clinical trials, including a Phase I/II trial named FOCUS and two Phase II trials called EXPLORE and HORIZON. Founded in 2016 in Stevenage, Herefordshire, by Andrew Lotery, David Kavanagh, and Peter Lachmann, Gyroscope seeks to provide innovative solutions for patients suffering from retinal diseases.

Amphista Therapeutics Limited is a biopharmaceutical company based in Motherwell, United Kingdom, established in 2017. The company specializes in targeted protein degradation technology to develop innovative cancer therapeutics. Amphista's approach focuses on harnessing the body's natural processes to selectively and efficiently degrade disease-causing proteins, aiming to create first-in-class treatments. By advancing novel methodologies in targeted protein degradation, Amphista seeks to improve therapeutic efficacy and modulate protein abundance linked to disease progression, ultimately enhancing patient outcomes in oncology.

Oxular Limited is a clinical-stage company based in Oxford, United Kingdom, focused on developing innovative retinal treatments to address various retinal diseases. Founded in 2014, the company specializes in tissue-specific drug delivery technology aimed at improving the effectiveness of treatments for conditions such as age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and cystoid macular edema. By targeting specific areas within the eye, Oxular seeks to enhance therapeutic outcomes while minimizing side effects and reducing the frequency of treatments, thereby offering patients effective and life-changing solutions for their unmet medical needs.

Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer. The company's immunotherapies harness the immune system to destroy cancer cells that target truncal tumor neo-antigens and flags to the immune system present on the surface of every cancer cell, enabling scientists to target and destroy tumors without harming healthy tissues.

CatalYm GmbH, founded in 2016 and based in Munich, Germany, is a biotechnology company focused on developing innovative immunotherapies for cancer patients. The company has identified GDF-15 as a key regulator of the immune system within the tumor microenvironment. By neutralizing GDF-15, CatalYm aims to enhance the immune response against solid tumors, potentially leading to meaningful clinical outcomes. Its CTL-002 program is designed to demonstrate clinical proof-of-concept across multiple solid tumor indications, offering the prospect of expanding treatment options for cancer patients. Through its approach, CatalYm seeks to transform the tumor microenvironment, making tumors more accessible to the immune system and improving both survival rates and quality of life for patients.

Prilenia is a clinical-stage biotechnology company focused on developing innovative treatments for neurodegenerative and neurodevelopmental disorders. Founded in 2018, the company operates from locations in Israel, the Netherlands, and Boston. Its primary asset is Pridopidine, an oral drug candidate that has demonstrated an established safety profile and shows promise in treating various movement disorders and neurodegenerative diseases in both adults and children. Prilenia aims to enhance the functional capacity of patients, particularly those undergoing early hemodialysis, by addressing the underlying challenges posed by these conditions.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

Azafaros B.V., based in Leiden, the Netherlands, is focused on developing therapeutic agents for rare metabolic disorders, particularly lysosomal storage disorders (LSDs). The company specializes in oral administration of aza-sugar compounds, which were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros. These innovative agents aim to address key disease pathways by targeting the central nervous system and interfering with the metabolism of glycosphingolipids. Through a unique dual mode of action, Azafaros seeks to improve the lives of patients suffering from these severe and often life-threatening inherited diseases.

NorthSea Therapeutics B.V. is a biotechnology company focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Established in 2017 and based in Naarden, the Netherlands, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutic candidates. One of its leading products, icosabutate, is designed to address inflammatory and liver diseases by offering a novel approach to treatment. The company's pipeline includes candidates that aim to improve conditions such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, providing healthcare providers with effective options for patient care.

Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer. The company's immunotherapies harness the immune system to destroy cancer cells that target truncal tumor neo-antigens and flags to the immune system present on the surface of every cancer cell, enabling scientists to target and destroy tumors without harming healthy tissues.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

SANIFIT is a biotechnology company that develops treatments for patients with calcification disorders.

Inflazome Ltd. is a biotechnology company based in Dublin, Ireland, founded in 2016. It specializes in developing orally available drugs aimed at addressing unmet clinical needs in inflammatory diseases by targeting the inflammasome, a component involved in the inflammatory process. The company’s innovative therapies are designed to block inflammasome signals, effectively tackling various inflammatory-driven conditions. These include orphan diseases, central nervous system disorders such as Alzheimer's and Parkinson's, systemic inflammatory diseases like cardiovascular and pulmonary conditions, and applications in ophthalmology and dermatology. By targeting the root causes of inflammation, Inflazome enables the development of precise treatments for a range of diseases, thereby enhancing therapeutic options for healthcare providers. As of September 2020, Inflazome operates as a subsidiary of Roche Holding AG.

OMEICOS Therapeutics GmbH is a Berlin-based company founded in 2013 that specializes in developing novel therapeutics for cardiovascular diseases and other health conditions. The company focuses on small molecule therapies derived from natural metabolites of omega-3 fatty acids, which exhibit a unique mode of action. These substances activate an endogenous cardio-protective signaling pathway, providing both anti-arrhythmic effects and curative benefits by stabilizing heart rhythm and preventing electrical and structural remodeling of the heart. In addition to cardiovascular applications, OMEICOS also explores treatments for inflammatory and ophthalmic diseases, aiming to deliver safe and effective therapeutic options for various medical indications.

Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, focused on developing and commercializing etripamil for various cardiovascular conditions. Etripamil is a novel short-acting calcium channel blocker designed to be administered as a rapid-onset nasal spray, specifically targeting the termination of episodes of paroxysmal supraventricular tachycardia (PSVT). The company is currently conducting Phase III clinical trials for etripamil in the treatment of PSVT and is also exploring its potential applications for atrial fibrillation, angina, and other related cardiovascular disorders. Founded in 2003, Milestone Pharmaceuticals aims to address unmet medical needs in cardiovascular disease management through innovative therapeutic solutions.

Gotham Therapeutics is a biotechnology company based in New York that focuses on developing a novel class of drugs targeting epitranscriptomics machinery. Founded in 2017, the company aims to provide new treatment options for patients with cancers, autoimmune disorders, and neurodegenerative diseases. Its approach involves creating small molecules that modify the activity of messenger ribonucleic acid (mRNA) to influence protein transcription. This innovative strategy allows Gotham Therapeutics to potentially optimize therapeutic outcomes for individuals suffering from serious health conditions.

KaNDy Therapeutics is a biotechnology company based in Stevenage, United Kingdom, focused on developing non-hormonal treatments for various menopausal symptoms, including hot flashes and nighttime awakenings. Established in 2017, the company is known for its drug NT-814, which addresses moderate to severe post-menopausal vasomotor symptoms. By providing non-hormonal therapies, KaNDy Therapeutics aims to alleviate the debilitating effects of hormone-related conditions in women. As a subsidiary of Bayer Aktiengesellschaft, the company leverages its research and development capabilities to enhance the quality of life for patients experiencing these common symptoms.

NorthSea Therapeutics B.V. is a biotechnology company focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Established in 2017 and based in Naarden, the Netherlands, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutic candidates. One of its leading products, icosabutate, is designed to address inflammatory and liver diseases by offering a novel approach to treatment. The company's pipeline includes candidates that aim to improve conditions such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, providing healthcare providers with effective options for patient care.

Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics for infectious diseases and cancers using its proprietary arenavirus platform. The company’s lead product candidate for infectious diseases, HB-101, is currently undergoing a randomized double-blinded Phase II clinical trial for patients awaiting kidney transplants from cytomegalovirus-positive donors. In oncology, Hookipa is advancing its candidates HB-201 and HB-202, which target human papillomavirus-positive cancers and are in preclinical studies. The company employs its innovative VaxWave and TheraT platforms to stimulate robust immune responses, generating high levels of antigen-specific killer T cells and antibodies, which are essential for effective treatment. Additionally, Hookipa has partnered with Gilead Sciences to develop therapies aimed at achieving functional cures for chronic hepatitis B and HIV infections. Founded in 2011 and based in New York, Hookipa Pharma is dedicated to transforming the landscape of immune therapies.

Replimune Group is a biotechnology company focused on developing oncolytic immune-gene therapies for cancer treatment. Utilizing its proprietary Immulytic platform, Replimune aims to create product candidates that activate the immune system against tumors. The company's lead candidate, RP1, is a modified herpes simplex virus currently undergoing Phase I/II clinical trials for various solid tumors and Phase II trials specifically for cutaneous squamous cell carcinoma. Additionally, Replimune is developing RP2, which targets CTLA-4 to enhance immune response, and RP3, designed to express immune-activating proteins that stimulate T cells. Founded in 2015 and based in Woburn, Massachusetts, Replimune seeks to advance its therapies through clinical trials and explore combinations with other immuno-oncology treatments to enhance efficacy.

Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, focused on developing and commercializing etripamil for various cardiovascular conditions. Etripamil is a novel short-acting calcium channel blocker designed to be administered as a rapid-onset nasal spray, specifically targeting the termination of episodes of paroxysmal supraventricular tachycardia (PSVT). The company is currently conducting Phase III clinical trials for etripamil in the treatment of PSVT and is also exploring its potential applications for atrial fibrillation, angina, and other related cardiovascular disorders. Founded in 2003, Milestone Pharmaceuticals aims to address unmet medical needs in cardiovascular disease management through innovative therapeutic solutions.

Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics for infectious diseases and cancers using its proprietary arenavirus platform. The company’s lead product candidate for infectious diseases, HB-101, is currently undergoing a randomized double-blinded Phase II clinical trial for patients awaiting kidney transplants from cytomegalovirus-positive donors. In oncology, Hookipa is advancing its candidates HB-201 and HB-202, which target human papillomavirus-positive cancers and are in preclinical studies. The company employs its innovative VaxWave and TheraT platforms to stimulate robust immune responses, generating high levels of antigen-specific killer T cells and antibodies, which are essential for effective treatment. Additionally, Hookipa has partnered with Gilead Sciences to develop therapies aimed at achieving functional cures for chronic hepatitis B and HIV infections. Founded in 2011 and based in New York, Hookipa Pharma is dedicated to transforming the landscape of immune therapies.

CatalYm GmbH, founded in 2016 and based in Munich, Germany, is a biotechnology company focused on developing innovative immunotherapies for cancer patients. The company has identified GDF-15 as a key regulator of the immune system within the tumor microenvironment. By neutralizing GDF-15, CatalYm aims to enhance the immune response against solid tumors, potentially leading to meaningful clinical outcomes. Its CTL-002 program is designed to demonstrate clinical proof-of-concept across multiple solid tumor indications, offering the prospect of expanding treatment options for cancer patients. Through its approach, CatalYm seeks to transform the tumor microenvironment, making tumors more accessible to the immune system and improving both survival rates and quality of life for patients.

Allecra Therapeutics, a clinical stage biopharmaceutical company, was established in 2013 and is dedicated to the development of novel treatments to combat multi drug-resistant bacterial infections. Allecra has a novel β-lactamase inhibitor in Phase 2 clinical development. By inhibiting β-lactamases Allecra’s new medicine directly tackles emerging resistance mechanisms of certain hard-to-treat bacteria. These resistance mechanisms are often found in hospital-acquired Gram-negative bacterial infections, and are of particular concern to doctors, healthcare providers, to patients and their families and to governments around the world. Allecra Therapeutics is situated in the BioValley Life Sciences region in the Upper Rhein valley whichencompasses northwest Switzerland, southwestern Germany and the Alsace region of France

Akarna Therapeutics is a biopharmaceutical company with offices in San Diego and Cambridge (UK) that is developing novel small molecule therapeutics that target inflammatory and fibrotic diseases. Our lead program is a non-bile acid FXR agonist that is potentially a best-in-class therapeutic for the treatment of nonalcoholic steatohepatitis (NASH), a progressive form of fatty-liver disease for which there are no approved therapies. Akarna’s lead candidate is currently in preclinical, IND-enabling toxicology and safety pharmacology studies with first-in-human studies planned for early 2017.

Exosome Diagnostics, Inc. specializes in the development and commercialization of biofluid-based molecular diagnostic tests aimed at enhancing personalized precision healthcare. The company employs a proprietary exosome technology platform that extracts and analyzes molecular information from exosomes present in various biofluids, including blood, urine, and cerebrospinal fluid. This approach enables non-invasive diagnostics for serious diseases, significantly reducing the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that simultaneously analyzes exosomal RNA and circulating tumor DNA in a single assay to identify actionable mutations across multiple cancer types. By combining RNA, DNA, and protein analysis, Exosome Diagnostics provides comprehensive molecular insights that can transform the detection, diagnosis, treatment, and monitoring of cancer and other serious conditions. The company also collaborates with pharmaceutical firms to enhance research and development processes, including biomarker discovery and the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, Exosome Diagnostics operates as a subsidiary of Bio-Techne Corporation.

Replimune Group is a biotechnology company focused on developing oncolytic immune-gene therapies for cancer treatment. Utilizing its proprietary Immulytic platform, Replimune aims to create product candidates that activate the immune system against tumors. The company's lead candidate, RP1, is a modified herpes simplex virus currently undergoing Phase I/II clinical trials for various solid tumors and Phase II trials specifically for cutaneous squamous cell carcinoma. Additionally, Replimune is developing RP2, which targets CTLA-4 to enhance immune response, and RP3, designed to express immune-activating proteins that stimulate T cells. Founded in 2015 and based in Woburn, Massachusetts, Replimune seeks to advance its therapies through clinical trials and explore combinations with other immuno-oncology treatments to enhance efficacy.

SANIFIT is a biotechnology company that develops treatments for patients with calcification disorders.

Exosome Diagnostics, Inc. specializes in the development and commercialization of biofluid-based molecular diagnostic tests aimed at enhancing personalized precision healthcare. The company employs a proprietary exosome technology platform that extracts and analyzes molecular information from exosomes present in various biofluids, including blood, urine, and cerebrospinal fluid. This approach enables non-invasive diagnostics for serious diseases, significantly reducing the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that simultaneously analyzes exosomal RNA and circulating tumor DNA in a single assay to identify actionable mutations across multiple cancer types. By combining RNA, DNA, and protein analysis, Exosome Diagnostics provides comprehensive molecular insights that can transform the detection, diagnosis, treatment, and monitoring of cancer and other serious conditions. The company also collaborates with pharmaceutical firms to enhance research and development processes, including biomarker discovery and the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, Exosome Diagnostics operates as a subsidiary of Bio-Techne Corporation.

Replimune Group is a biotechnology company focused on developing oncolytic immune-gene therapies for cancer treatment. Utilizing its proprietary Immulytic platform, Replimune aims to create product candidates that activate the immune system against tumors. The company's lead candidate, RP1, is a modified herpes simplex virus currently undergoing Phase I/II clinical trials for various solid tumors and Phase II trials specifically for cutaneous squamous cell carcinoma. Additionally, Replimune is developing RP2, which targets CTLA-4 to enhance immune response, and RP3, designed to express immune-activating proteins that stimulate T cells. Founded in 2015 and based in Woburn, Massachusetts, Replimune seeks to advance its therapies through clinical trials and explore combinations with other immuno-oncology treatments to enhance efficacy.

enGene is a developer of a mucosal immunotherapy platform designed to treat inflammatory bowel disease and diabetes. The company's mucosal immunotherapy platform has developed a flexible nucleotide delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expression levels, enabling physicians and doctors to regenerate physiologic, meal-regulated insulin secretion from the gut of subjects with diabetes.

Exosome Diagnostics, Inc. specializes in the development and commercialization of biofluid-based molecular diagnostic tests aimed at enhancing personalized precision healthcare. The company employs a proprietary exosome technology platform that extracts and analyzes molecular information from exosomes present in various biofluids, including blood, urine, and cerebrospinal fluid. This approach enables non-invasive diagnostics for serious diseases, significantly reducing the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that simultaneously analyzes exosomal RNA and circulating tumor DNA in a single assay to identify actionable mutations across multiple cancer types. By combining RNA, DNA, and protein analysis, Exosome Diagnostics provides comprehensive molecular insights that can transform the detection, diagnosis, treatment, and monitoring of cancer and other serious conditions. The company also collaborates with pharmaceutical firms to enhance research and development processes, including biomarker discovery and the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, Exosome Diagnostics operates as a subsidiary of Bio-Techne Corporation.

Ario Pharma Ltd is focused on developing therapeutic drugs for respiratory conditions, particularly through the evaluation of XEN-D0501, a potential leading TRPV1 inhibitor. The company is conducting two Phase 2 clinical trials to assess the anti-tussive properties of this drug. In addition to its respiratory portfolio, Ario also works on small-molecule TRPV1 antagonists aimed at treating neuropathic and inflammatory pain. The firm is backed by a skilled development team and supported by leading experts in respiratory diseases, ensuring a robust approach to drug development.

Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, focused on developing personalized immunotherapies for cancer, infectious diseases, and autoimmune disorders. It utilized its proprietary Arcelis technology platform to create individualized treatments, including rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, in Phase II trials for human immunodeficiency virus. The company's product pipeline also included therapies aimed at transplant rejection and autoimmune conditions. Founded in 1997 and originally named Merix Bioscience, Argos Therapeutics aimed to address significant unmet medical needs in the field of immuno-oncology. However, on September 24, 2019, the company filed for Chapter 7 bankruptcy, leading to its cessation of operations.

Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics for infectious diseases and cancers using its proprietary arenavirus platform. The company’s lead product candidate for infectious diseases, HB-101, is currently undergoing a randomized double-blinded Phase II clinical trial for patients awaiting kidney transplants from cytomegalovirus-positive donors. In oncology, Hookipa is advancing its candidates HB-201 and HB-202, which target human papillomavirus-positive cancers and are in preclinical studies. The company employs its innovative VaxWave and TheraT platforms to stimulate robust immune responses, generating high levels of antigen-specific killer T cells and antibodies, which are essential for effective treatment. Additionally, Hookipa has partnered with Gilead Sciences to develop therapies aimed at achieving functional cures for chronic hepatitis B and HIV infections. Founded in 2011 and based in New York, Hookipa Pharma is dedicated to transforming the landscape of immune therapies.

uniQure is a pioneering gene therapy company recognized for developing the first gene therapy product to receive regulatory approval in the European Union. Its initial product, Glybera, was authorized in October 2012 for treating patients with lipoprotein lipase deficiency, a rare and severe metabolic disorder. uniQure specializes in creating innovative gene therapies that offer long-term and potentially curative benefits for genetic and acquired diseases. The company utilizes a modular technology platform and a proprietary manufacturing process to develop its treatments. Currently, uniQure is expanding its pipeline of adeno-associated virus (AAV)-based gene therapies, focusing on conditions such as hemophilia, Huntington's disease, and cardiovascular diseases through collaborations, including one with Bristol Myers Squibb. While the company initially targets orphan diseases, it also aims to address chronic and degenerative diseases affecting larger populations.

Allecra Therapeutics, a clinical stage biopharmaceutical company, was established in 2013 and is dedicated to the development of novel treatments to combat multi drug-resistant bacterial infections. Allecra has a novel β-lactamase inhibitor in Phase 2 clinical development. By inhibiting β-lactamases Allecra’s new medicine directly tackles emerging resistance mechanisms of certain hard-to-treat bacteria. These resistance mechanisms are often found in hospital-acquired Gram-negative bacterial infections, and are of particular concern to doctors, healthcare providers, to patients and their families and to governments around the world. Allecra Therapeutics is situated in the BioValley Life Sciences region in the Upper Rhein valley whichencompasses northwest Switzerland, southwestern Germany and the Alsace region of France

Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing therapeutics for rare fibrotic and inflammatory diseases. The company’s primary targets include conditions such as myelofibrosis, idiopathic pulmonary fibrosis, age-related macular degeneration, and diabetic retinopathy. Promedior's drug portfolio features PRM-151, a recombinant form of human pentaxin-2 protein, and PRM-167, a variant designed for intravitreal delivery. These therapeutics are aimed at regulating monocyte-derived cell populations, which are critical in fibrotic, inflammatory, and autoimmune diseases. By specifically addressing these cells at injury sites, Promedior seeks to promote tissue healing and minimize systemic side effects commonly associated with existing therapies. The company was incorporated in 2006 and was previously known as Fibrotix, Inc.

Bluebird Bio is a biotechnology company focused on the research, development, and commercialization of innovative gene therapies for severe genetic diseases and cancer. Its gene therapy programs include LentiGlobin, aimed at treating β-thalassemia and sickle cell disease, and Lenti-D, for cerebral adrenoleukodystrophy. In oncology, Bluebird Bio is developing chimeric antigen receptor T (CAR T) cell therapies, specifically bb2121 and bb21217, for multiple myeloma. The company collaborates with several partners, including Bristol-Myers Squibb and Regeneron Pharmaceuticals, to discover and commercialize disease-altering therapies. Additional collaborations with organizations such as Medigene AG and Gritstone Oncology focus on developing T cell receptor product candidates for cancer treatment. Founded in 1992 and headquartered in Cambridge, Massachusetts, Bluebird Bio aims to fundamentally address the genetic basis of diseases through its proprietary lentiviral vector gene addition platform. Revenue is generated from collaboration agreements, research fees, license fees, and grants.

Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing therapeutics for rare fibrotic and inflammatory diseases. The company’s primary targets include conditions such as myelofibrosis, idiopathic pulmonary fibrosis, age-related macular degeneration, and diabetic retinopathy. Promedior's drug portfolio features PRM-151, a recombinant form of human pentaxin-2 protein, and PRM-167, a variant designed for intravitreal delivery. These therapeutics are aimed at regulating monocyte-derived cell populations, which are critical in fibrotic, inflammatory, and autoimmune diseases. By specifically addressing these cells at injury sites, Promedior seeks to promote tissue healing and minimize systemic side effects commonly associated with existing therapies. The company was incorporated in 2006 and was previously known as Fibrotix, Inc.

Argenx is a global immunology company based in the Netherlands, dedicated to enhancing the lives of individuals affected by severe autoimmune diseases and cancer. The company employs advanced antibody engineering technology to develop treatments for rare autoimmune conditions. Its notable product, Vyvgart (efgartigimod), received initial approval in the United States in December 2021 for the treatment of generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022. Through its innovative approaches, Argenx aims to address unmet medical needs in the field of immunology.

Oxyrane UK Limited is a biopharmaceutical company focused on developing innovative enzyme replacement therapies for lysosomal storage diseases, which encompass over 40 rare inherited disorders. Established in 2006 and headquartered in Manchester, United Kingdom, the company utilizes a proprietary glycoengineering platform based on the yeast Yarrowia lipolytica to produce human lysosomal enzymes that enhance enzyme uptake and localization in patients. Oxyrane's approach aims to expedite treatment initiation and improve the chances of successful outcomes for individuals affected by these conditions. Additionally, the company operates research facilities in Ghent, Belgium, and maintains a presence in Burlington, Massachusetts.

Amakem is a kinase platform company focusing on ophthalmology and is developing new treatments for serious eye conditions. Amakem's product pipeline is based on its unique ‘Localized Drug Action' platform which is designed to generate safe and effective novel kinase inhibitors that minimize systemic exposure with the aim of reducing side effects.

Bluebird Bio is a biotechnology company focused on the research, development, and commercialization of innovative gene therapies for severe genetic diseases and cancer. Its gene therapy programs include LentiGlobin, aimed at treating β-thalassemia and sickle cell disease, and Lenti-D, for cerebral adrenoleukodystrophy. In oncology, Bluebird Bio is developing chimeric antigen receptor T (CAR T) cell therapies, specifically bb2121 and bb21217, for multiple myeloma. The company collaborates with several partners, including Bristol-Myers Squibb and Regeneron Pharmaceuticals, to discover and commercialize disease-altering therapies. Additional collaborations with organizations such as Medigene AG and Gritstone Oncology focus on developing T cell receptor product candidates for cancer treatment. Founded in 1992 and headquartered in Cambridge, Massachusetts, Bluebird Bio aims to fundamentally address the genetic basis of diseases through its proprietary lentiviral vector gene addition platform. Revenue is generated from collaboration agreements, research fees, license fees, and grants.

PneumRx, Inc. is a medical device company founded in 2004 and based in Mountain View, California. The company specializes in developing minimally invasive treatments specifically for patients suffering from emphysema. Its primary product is the RePneu Lung Volume Reduction Coil, an investigational device designed to improve lung function and quality of life for individuals affected by this chronic respiratory condition.

Cytheris is a privately held clinical-stage biopharmaceutical company focused on research and development of therapies for immune modulation. These drugs aim at reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial infections such as HIV, HCV, and HBV or lympho-depleting treatments such as chemotherapy, radiotherapy, bone marrow transplantation (BMT) and hematopoietic cell transplantation (HCT).

Exosome Diagnostics, Inc. specializes in the development and commercialization of biofluid-based molecular diagnostic tests aimed at enhancing personalized precision healthcare. The company employs a proprietary exosome technology platform that extracts and analyzes molecular information from exosomes present in various biofluids, including blood, urine, and cerebrospinal fluid. This approach enables non-invasive diagnostics for serious diseases, significantly reducing the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that simultaneously analyzes exosomal RNA and circulating tumor DNA in a single assay to identify actionable mutations across multiple cancer types. By combining RNA, DNA, and protein analysis, Exosome Diagnostics provides comprehensive molecular insights that can transform the detection, diagnosis, treatment, and monitoring of cancer and other serious conditions. The company also collaborates with pharmaceutical firms to enhance research and development processes, including biomarker discovery and the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, Exosome Diagnostics operates as a subsidiary of Bio-Techne Corporation.

Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing therapeutics for rare fibrotic and inflammatory diseases. The company’s primary targets include conditions such as myelofibrosis, idiopathic pulmonary fibrosis, age-related macular degeneration, and diabetic retinopathy. Promedior's drug portfolio features PRM-151, a recombinant form of human pentaxin-2 protein, and PRM-167, a variant designed for intravitreal delivery. These therapeutics are aimed at regulating monocyte-derived cell populations, which are critical in fibrotic, inflammatory, and autoimmune diseases. By specifically addressing these cells at injury sites, Promedior seeks to promote tissue healing and minimize systemic side effects commonly associated with existing therapies. The company was incorporated in 2006 and was previously known as Fibrotix, Inc.

Bluebird Bio is a biotechnology company focused on the research, development, and commercialization of innovative gene therapies for severe genetic diseases and cancer. Its gene therapy programs include LentiGlobin, aimed at treating β-thalassemia and sickle cell disease, and Lenti-D, for cerebral adrenoleukodystrophy. In oncology, Bluebird Bio is developing chimeric antigen receptor T (CAR T) cell therapies, specifically bb2121 and bb21217, for multiple myeloma. The company collaborates with several partners, including Bristol-Myers Squibb and Regeneron Pharmaceuticals, to discover and commercialize disease-altering therapies. Additional collaborations with organizations such as Medigene AG and Gritstone Oncology focus on developing T cell receptor product candidates for cancer treatment. Founded in 1992 and headquartered in Cambridge, Massachusetts, Bluebird Bio aims to fundamentally address the genetic basis of diseases through its proprietary lentiviral vector gene addition platform. Revenue is generated from collaboration agreements, research fees, license fees, and grants.

Transave, Inc., a biotechnology company, develops inhaled pharmaceuticals for the treatment of lung diseases. The company’s liposomal technology allows the release of drug in the lung's microenvironment. Its products also include Arikace for the treatment of gram-negative lung infections and pseudomonas infections in cystic fibrosis patients; and cisplatin lipid complex for the treatment of cancers affecting the lungs. Transave, Inc. was founded in 1997 and is headquartered in Monmouth Junction, New Jersey. As of December 1, 2010, Transave, Inc. operates as a subsidiary of Insmed Incorporated.

PanGenetics B.V. develops monoclonal antibodies for the treatment of immune mediated diseases. PanGenetics is a clinical development company that specializes in taking antibodies from the late research stage through to clinical proof of concept. The company is based in Utrecht, the Netherlands with an office in Cambridge, UK. PanGenetics employs a lean business model with manufacturing and clinical development activities outsourced to specialist providers. Apart from PG110, the other clinical program of PanGenetics is PG102, a CD40 antagonist for treatment of autoimmune diseases which is currently being evaluated in a clinical study in psoriatic arthritis patients

Fovea Pharmaceuticals is a French biopharmaceutical company. It discovers and develops drugs for the treatment of ocular diseases. The company offers FOV1101 Prednisporin for the treatment of allergic conjunctivitis; FOV2302, a proprietary plasma kallikrein-kinin inhibitor for the systemic treatment of hereditary angioedema; FOV2304 for the treatment of diabetic macular edema; and FOV2501, an intravitreal formulation of RdCVF designed to treat retinitis pigmentosa with extension to dry age-related macular degeneration. Fovea Pharmaceuticals was founded in 2005 and is based in Paris, France. As of October 30, 2009, it operates as a subsidiary of Sanofi.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

Pieris Pharmaceuticals is a clinical-stage biotechnology company that develops drugs to fight cancer, severe asthma, anemia, and other medical conditions with unmet medical needs. The company applies its proprietary Anticalin® technology to the drug development processes. Pieris Pharmaceuticals was founded in 2001 and is based in Freising, Bayern.

Xention Limited is a biopharmaceutical company based in Cambridge, United Kingdom, that focuses on discovering and developing innovative ion channel-modulating drugs. Founded in 2002, the company aims to address significant unmet medical needs by creating therapies for conditions such as atrial fibrillation, overactive bladder, pain, and autoimmune diseases. Xention develops drug candidates that target two novel yet well-characterized ion channels, striving to produce breakthrough therapies that enhance treatment options in these areas. The company, originally known as Xention Discovery Ltd., rebranded to Xention Limited in October 2006.

Borean Pharma ApS operates as a drug discovery and development company. The company's technology platform enables to design, develop, and produce pharmaceutical protein products. The company focuses on recombinant protein technology, as well as on antibody biopharmaceuticals. It offers protein products, antibody analogues, and CTLD library, as well as TNF antagonist for rheumatoid arthritis. The company was founded in 1997 and is based in Aarhus, Denmark.

FlowMedica is a medical device company that specializes in intravascular systems for Targeted Renal Therapy, addressing renal conditions linked to cardiovascular disease, cancer, and surgical procedures. The company's flagship products include the Benephit CV Infusion System, which allows physicians to deliver therapeutic agents directly into the renal arteries via an infusion catheter, while facilitating simultaneous coronary procedures through a single access site in the femoral artery. Additionally, FlowMedica offers the Benephit XTMini Infusion System, designed for bilateral infusion to the kidneys, particularly beneficial for patients with smaller vascular anatomies. By providing a targeted approach to renal therapy, FlowMedica's devices serve as an effective alternative to traditional systemic intravenous infusion methods, enabling precise delivery in various clinical scenarios.

Roche Glycart develops antibody drug candidates, which include GA101, a humanized anti-CD20 monoclonal antibody to increase direct- and immune-mediated target cell death; and GA201, a humanized glycoengineered antibody for solid tumors.

Acorda Therapeutics is a biopharmaceutical company focused on developing and commercializing therapies for neurological disorders in the United States and internationally. The company’s primary product, Ampyra (dalfampridine), is an oral medication approved to enhance walking in patients with multiple sclerosis. Additionally, Acorda markets Inbrija, an inhalation powder for the treatment of OFF periods in individuals with Parkinson's disease. The company's pipeline includes rHIgM22, which has completed Phase I trials for multiple sclerosis, and Cimaglermin alfa, currently in Phase Ib trials for heart failure. Acorda has established a collaboration with Biogen for the development and commercialization of Ampyra. Founded in 1995 and based in Ardsley, New York, Acorda Therapeutics aims to improve the quality of life for those affected by neurological conditions.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing small molecule drugs for central nervous system disorders. Founded in 1993 and headquartered in San Diego, California, the company is best known for its product NUPLAZID (pimavanserin), which is approved for treating hallucinations and delusions associated with Parkinson’s disease psychosis. Acadia is actively advancing pimavanserin through Phase III clinical trials for dementia-related psychosis and as an adjunctive treatment for schizophrenia, as well as exploring its use for major depressive disorder. The company operates two subsidiaries in Sweden and Denmark and is committed to discovering novel treatments for conditions such as Alzheimer's and schizophrenia, while also seeking to in-license or acquire complementary products. Acadia holds several patent applications related to its proprietary technology, including innovative methods for drug discovery and development.

Transave, Inc., a biotechnology company, develops inhaled pharmaceuticals for the treatment of lung diseases. The company’s liposomal technology allows the release of drug in the lung's microenvironment. Its products also include Arikace for the treatment of gram-negative lung infections and pseudomonas infections in cystic fibrosis patients; and cisplatin lipid complex for the treatment of cancers affecting the lungs. Transave, Inc. was founded in 1997 and is headquartered in Monmouth Junction, New Jersey. As of December 1, 2010, Transave, Inc. operates as a subsidiary of Insmed Incorporated.

Ardana Bioscience was created in July 2000 to commercialise research by the Medical Research Council (MRC )'s Human Reproductive Sciences Unit (HRSU) in Edinburgh, Scotland which has been at the forefront of this area of research for the last 28 years. The MRC employs nearly 100 staff at the Unit which currently receives total annual funding of £3.8 million.